Local concentrations of mutations are well known in human cancers. However, their three-dimensional spatial relationships in the encoded protein have yet to be systematically explored. We developed a computational tool, HotSpot3D, to identify such spatial hotspots (clusters) and to interpret the potential function of variants within them. We applied HotSpot3D to >4,400 TCGA tumors across 19 cancer types, discovering >6,000 intra- and intermolecular clusters, some of which showed tumor and/or tissue specificity. In addition, we identified 369 rare mutations in genes including TP53, PTEN, VHL, EGFR, and FBXW7 and 99 medium-recurrence mutations in genes such as RUNX1, MTOR, CA3, PI3, and PTPN11, all mapping within clusters having potential functional implications. As a proof of concept, we validated our predictions in EGFR using high-throughput phosphorylation data and cell-line-based experimental evaluation. Finally, mutation-drug cluster and network analysis predicted over 800 promising candidates for druggable mutations, raising new possibilities for designing personalized treatments for patients carrying specific mutations.
With tens of thousands of tumor-normal tissue pairs already sequenced, the accumulation of cancer genomic data continues to accelerate. The vast majority of mutations are incidental, with no discernible role in tumor development. Various computational approaches [1] [2] [3] [4] [5] [6] have been developed to winnow mutation lists down to driver mutations, including methods searching for genes or pathways having mutation rates higher than that explained by chance, gene pairs having either mutually exclusive or co-occurring mutations, or genes having neighboring mutations on the linear DNA or protein sequence.
Mutational impact on protein structure has not yet been systematically analyzed, but recent developments are moving in this direction. For example, MuPIT 7 , an extension of LS-SNP/PDB 8 , maps sequence variants onto protein structures, Interactome3D 9 annotates proteinprotein interactions with structural details, other web tools [10] [11] [12] map and visualize variants on protein structures, SpacePAC 13 identifies mutation clusters via simulation, CLUMPS 14 clusters cancer-associated genes and examines protein-protein interactions where at least one protein is known to be related to cancer, and Mechismo identifies interaction sites contributing to the binding forces between proteins and other peptides 15 . However, no system yet provides comprehensive analysis as a means to understanding the consequences or implications of mutations in drug delivery.
Here we present a new computational tool, HotSpot3D, which identifies mutation-mutation and mutation-drug clusters using three-dimensional protein structures and correlates these clusters with known or potentially interacting functional variants, domains, and proteins. We describe its testing and subsequent application to more than 4,000 tumors across 19 cancer types from The Cancer Genome Atlas (TCGA). Over 6,000 interaction clusters are identified, many of which are likely undetectable by conventional approaches, with a subset supported by high-throughput phosphorylation data and cell-line-based experimental evaluation included in this study, as well as accumulated experimental evidence [16] [17] [18] . We also report 800 promising candidate druggable mutations, generally characterized by complex, multidimensional interactions between drugs and variants. The list furnishes substantial possibilities for future therapeutics.
RESULTS

Intra- and intermolecular clusters across 19 cancer types
HotSpot3D is a multifaceted tool that integrates gene-sequence mutations with three-dimensional protein structures (Online Methods and Supplementary Note). It identifies significant spatial mutationmutation and mutation-drug clusters in the form of newly identified a n a ly s i s or rare variants co-clustering with known hotspot residues, mediumrecurrence variants that collectively exhibit enrichment, cancer-typespecific variant clusters within and in interacting proteins, and variants potentially interacting with drugs that target cancer and other diseases. HotSpot3D uses structures from the Protein Data Bank (PDB) 19 and variant and/or drug co-structures from DrugPort ( Fig. 1a and Online Methods). We evaluated clustering performance in HotSpot3D and compared our approach to existing tools to demonstrate its advancement in mutation cluster analysis (Fig. 1a-d and Supplementary Note).
We applied HotSpot3D to somatic non-truncating mutations (549,295 unique missense mutations and 4,201 in-frame indels) in 4,405 samples from 19 major cancer types (Online Methods). To identify potential intramolecular (within a single protein), intermolecular (between proteins in a complex), and variant-drug (for example, near a drug-binding pocket) interactions, we focused on detecting interaction pairs separated by less than 10 Å, which corresponds to the typical range for protein interactions 20 . We applied HotSpot3D to specifically target intramolecular variant pairs separated by at least 20 amino acids in the linear sequence of the protein (Online Methods). Clustering was performed on pairs with significant proximity (P < 0.05), and genes with clusters were ultimately compared to a list of 624 known cancer-related genes (Supplementary Note and Supplementary Table 1) .
Of the 5,822 intramolecular clusters identified, 698 clusters were in 244 known cancer-related proteins and 5,124 clusters were in 2,275 non-cancer-related proteins (Supplementary Tables 2 and 3) . Thirty-eight clusters (35 in cancer-related proteins and 3 in noncancer-related proteins) had cluster closeness (Cc) values above the threshold of Cc = 10.3 (Online Methods). The top five cancer-related proteins exhibiting high cluster closeness were TP53, KRAS, BRAF, IDH1, and PIK3CA, as expected and owing largely to the high mutation rates in the corresponding genes in cancer (Fig. 2a) . TP53 had the highest cluster closeness, as a result of both numerous variants in close proximity (192 unique variants) and variant recurrence (38 hotspot residues) throughout the protein. We observed a shift toward higher cluster closeness for variant clusters in cancer-related proteins as compared to non-cancer-related proteins (P ≈ 5.3 × 10 −13 ) (Fig. 2a, inset and Online Methods).
Clustering analysis of protein complexes resulted in the identification of 488 clusters, of which 34 comprised only cancer-related proteins, 122 contained at least one cancer-related protein, and 332 contained no cancer-related proteins (Supplementary Tables 2 and 4). As in the intramolecular analysis, we selected top intermolecular clusters (Cc > 4.1; Online Methods) for downstream analyses (Fig. 2b) . Of the 22 clusters that passed the threshold, clusters containing cancer-related proteins exhibited significantly (P = 0.004022) higher cluster closeness than those having no cancer-related proteins (Fig. 2b, inset) . ATRX 3QLN  CHEK1 1NVQ  CHEK1 2E9O  CUL4B 4A64  EGFR 3W2S  EGFR 4JRV  ESR1 2QGW  ESR2 3OMQ  GSK3B 1J1B  GSTP1 1AQW  HGF 4O3T  JAK1 4IVD  KDR 3B8R  MBD1 1IG4  MDM4 3U15  MET 3VW8  MRE11A 3T1I  MTAP 3OZC  NOTCH1 4D0F  PIK3CG 4FHK  POLH 4ECR  PRSS1 1TRN  RASA1 1WER  RB1 2R7G  RET 2IVT  RET 2X2L  SOD2 1SZX  SRC 1O4I  SYK 3TUC  SYK 4I0R  TYMS npg a n a ly s i s Oncogenes and tumor-suppressor genes (TSGs) had distinct mutational signatures, with the former characterized by recurrent variants at activating sites and the latter having a higher abundance of truncating variants scattered across their sequences 21 . However, the mutational patterns for non-truncating mutations have not been intensively studied in TSGs. When considering the proteins encoded by the 64 oncogenes and 74 TSGs classified by Vogelstein et al. 21 , we observed 124 and 89 intramolecular clusters for 36 oncogenes and 38 TSGs, respectively (Supplementary Fig. 1 and Supplementary Tables 5 and 6). Nine oncogenes (HRAS, KRAS, IDH1, IDH2, BRAF, PPP2R1A, SPOP, PIK3CA, and MAP2K1) and five TSGs (TP53, CDKN2A, B2M, FBXW7, and MAP2K4) accounted for >50% of the non-truncating variants included in clusters; the difference between oncogenes and TSGs in the number of genes with a majority of variants in clusters was not significant (P ≈ 0.4). Clusters in both categories tended to correlate with known functional domains, suggesting functional implications (Supplementary Tables 7 and 8 ).
Significant mutation clusters with cancer type specificity
To explore cancer type specificities for significant clusters, we performed unsupervised clustering of the cancers with the 38 intramolecular clusters (Cc >10.3) and the 22 intermolecular clusters (Cc >4.1) (Fig. 3 and Online Methods). Intramolecular clusters not associated with a specific cancer type included those in TP53, PIK3R1, and KRAS (Fig. 3a) . We further identified 18 intramolecular clusters in which at least 50% of mutations across all samples are specific to one cancer type (Supplementary Table 9 ), suggesting diverse roles for clusters in different cell types. High specificity was associated with VHL and MTOR, for which 95% and 86% of the respective variant clusters were specific to kidney renal clear cell carcinoma (KIRC), and DNMT3A, for which 91% of the variant clusters were specific to acute myeloid leukemia (LAML). Clusters with high specificity for a particular cancer type can result from a hotspot having most of its variants in one cancer type, as is the case with the Arg882 residue in DNMT3A. Conversely, VHL and MTOR showed a distribution of variants across multiple residues.
PIK3CA had six distinct top-scoring clusters exhibiting specificity for both uterine corpus endometrial carcinoma (UCEC) and breast invasive carcinoma (BRCA) (Fig. 3b) . The PIK3CA(4) cluster at centroid (the residue with the greatest closeness centrality within the cluster) Arg88 was primarily specific to UCEC (54% of variants) and had variants distributed among three different residues (Arg38, Glu39, and Arg88) that showed little specificity for BRCA. Conversely, the PIK3CA(1) cluster was primarily specific to BRCA (69% of variants), and the His1047 centroid was primarily responsible for the overall BRCA specificity. Finally, the PIK3CA(5) cluster with centroid Cys420 was present in multiple cancer types. We found mild specificity for glioblastoma multiforme (GBM) in PIK3CA across four residues (Arg38, Glu39, Arg88, and Cys90) in the PIK3CA(4) cluster and specificity for cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) at Glu726 in the PIK3CA(6) cluster. Epidermal growth factor receptor (EGFR) also had two different clusters that contributed to different cancer types (Fig. 3b) : a cluster in the extracellular domain, EGFR(1), with centroid Ala289 enriched Several intermolecular clusters also showed tumor specificity, with eight clusters >50% specific to one cancer type, including the well-known oncogenic protein complexes ASB9-SOCS4-TCEB1-VHL (KIRC), BTRC-CTNNB1 (UCEC), AKAP13-ARHGEF12-RHOA (head and neck squamous cell carcinoma, HNSC), PPP2R1A-PPP2R2A (UCEC), and CBFB-RUNX1 (BRCA) (Fig. 3c and Supplementary  Table 10 ). In the KEAP1-NFE2L2 complex, KEAP1 and NFE2L2 variants showed mutual exclusivity, with KEAP1 variants in LUAD and STAD adenocarcinomas and NFE2L2 variants in multiple other cancer types (Fig. 3d) . Two of the residues for which variants were identified, Arg415 and Arg483 in KEAP1, have been experimentally validated, and both have been shown to be in the KEAP1 binding pocket and to have a major role in the stability of the KEAP1-NFE2L2 complex 22 . We also identified four TCEB1 residues-Arg82, Ser67, Ser86, and Tyr79 in UCEC, BRCA, UCEC, and KIRC, respectively-where variants clustered with variants at seven VHL residues-Cys162, Leu153, Leu158, Leu169, Ser168, Gly114, and Val165-in KIRC; variation at Tyr79 in TCEB1 has been experimentally validated to disrupt the TCEB1-VHL complex 16 (Fig. 3d, Supplementary Fig. 2, Supplementary Table 11 , and Supplementary Note).
Discovery of rare and medium-recurrence functional mutations
Rare and medium-recurrence drivers are often missed by frequencybased approaches 1, 2 . We define hotspot residues as those mutated in at least five different patient samples, regardless of the amino acid change. Variants that fall in the same cluster as hotspot residues are considered potential new functional variants (Fig. 4) .
We found 100 hotspot residues and 249 potentially new functional variants ( Fig. 4a and Supplementary Table 12 ) clustered with hotspot residues in the intramolecular analysis. TP53, PTEN, VHL, EGFR, and FBXW7 contained the top five clusters contributing the most new functional variants. A KRAS cluster had the second highest cluster closeness value across all clusters, resulting from the high frequency of variants at the centroid and nearby hotspots. The centroid was Gly12 (found in 198 patient samples) and had multiple amino acid changes (including to cysteine, aspartic acid, serine, valine, alanine, and phenylalanine). For this particular cluster, there were three hotspot residues-Gly12, Gly13, and Gln61 (Fig. 5a) . Additional possible functional variants outside of hotspot residues included p.Ile36Met; p.Ala59Glu, p.Ala59Gly, and p.Ala59Thr (each Figure 1b . Each row represents a cluster, with the intensity of shading corresponding to the proportion of variants in a cluster observed in a particular cancer type across all samples. (b) Distribution of cancer type specificity for six PIK3CA (purple, green, blue, red, orange, and pink) and two EGFR (brown and gray) clusters at the residue level. Bubble size corresponds to the fraction of variants in each cluster that occur at specific residues (y axis) for each of the 19 cancer types (x axis). Bubble color corresponds to that of the clusters highlighted in a. (c) Heat map of the cancer type specificity of intermolecular clusters exceeding the cluster closeness threshold defined in Figure 1d . (d) Distribution of cancer type specificity for the KEAP1-NFE2L2 (red and blue, respectively) and VHL-TCEB1 (green and purple, respectively) clusters at the residue level. Colors correspond to the specific proteins that make up the cluster.
EGFR (2) PIK3CA (1) PIK3CA (6) PIK3CA (5) ERBB2 PIK3CA (2) PIK3CA ( D77   E79   T80   E82   G333   R415   G477   R483   G509   G524   G527   G603   UCEC  KIRC  HNSC  BRCA  STAD  LAML  LUAD  LUSC  THCA  KIRP  CESC  BLCA   S67  Y79  R82  S86  G114  L153  L158  C162  V165  S168 npg a n a ly s i s in one sample); and p.Glu62Lys. Notably, the p.Ala59Glu, p.Ala59Gly, and p.Ala59Thr substitutions had a geodesic length of only 3 Å from the highly mutated centroid at Gly12 in three-dimensional space, even though they were 47 amino acids apart from this residue in the linear protein sequence. Ala59 had higher closeness centrality than expected because of its close proximity to highly mutated residues (Gln61, Gly12, and Gly13). Likewise, the p.Ile36Met variant was more than 20 amino acids away from all hotspot residues in the cluster but had a geodesic distance of only 5.8 Å from Gly12. These five potential new functional variants could be good candidates for subsequent functional validation. Another interesting observation was a MAP2K1 cluster with its centroid at Pro124, which was recurrently mutated in seven patient samples. Additionally, this cluster contained another hotspot at Glu203, mutated five times (Fig. 5b) . Other potential functional candidates in this cluster included p.Arg47Gln (occurring only once but having a geodesic distance of 5.9 Å from the centroid) and p.Asn122Asp and p.Glu333Ala (likewise occurring once each but with geodesic distances of less than 10 Å from the centroid). Experimental evidence existed for our prediction that the rare mutation encoding p.Arg47Gln is functional in cancer (Supplementary Table 11 ). p.Arg47Gln led to increased phosphorylation of the downstream kinases ERK1 and ERK2 (ERK1/2), supporting the activating potential of the underlying mutation 17 . Similarly, we could uncover potentially new functional variants from intermolecular clusters. We found 33 hotspot residues and 120 potentially new functional variants, 4 of which were already observed in intramolecular clusters ( Fig. 4b and Supplementary Table 13) . Notable examples included SMAD2, SMAD3, and SMAD4 complexes. Two separate intermolecular clusters (Fig. 5c ) accounted for 28.6% of the SMAD2, SMAD3, and SMAD4 missense mutations and in-frame indels. For one of the clusters (Fig. 5c , purple), we were able to identify seven rare variants, each occurring only once, in SMAD2 (p.Leu442Val, p.Leu446Val, and p.Ser276Leu), SMAD3 (p.Gln405Leu), and SMAD4 (p.Asp355Gly, p.Pro356Leu, and p.Ser357Pro), with all in close spatial proximity to the SMAD4 Arg361 hotspot (p.Arg361Cys, p.Arg361His, p.Arg361Pro, and p.Arg361Ser). In addition, p.Asp450Asn in SMAD2 occurred only once and was the closest spatially (2.6 Å distant) to the SMAD4 hotspot residue, making it another functional candidate. Recent work confirms our prediction that variants (at Asp450 and Ser276 in SMAD2) in close proximity to the Arg361 hotspot in SMAD4 destabilize SMAD2-SMAD4 and SMAD3-SMAD4 complexes 18 (Supplementary Table 11 ).
Our analysis also identified five intramolecular cases above the cluster closeness threshold involving RUNX1, MTOR, CA3, PI3, and PTPN11. None had hotspot residues, but all contained variants with medium recurrence or rare variants that were spatially dense. All of the variants in each of the five clusters collectively contributed to the high cluster closeness, and these could all correspond to new functional mutations (Supplementary Table 14) . For example, the cluster in RUNX1 contained Arg162 recurrently mutated four times, Pro113 mutated twice, and four other sites with singleton variants (p.Leu161Pro, p.Val118Ala, p.Asp160Gly, and p.Ala134Pro).
In terms of intermolecular cases, there were nine clusters with cluster closeness above threshold but no hotspot residues (Supplementary Table 15 ). The cluster with SMAD2, SMAD3, and SMAD4 (Fig. 5c , orange) contained Asp537 (SMAD4) mutated four times, Arg268 (SMAD3) mutated three times, Pro305 (SMAD2) mutated twice, and four residues with singleton variants (Arg531 and Leu533 in SMAD4 and Asp304 and Asp300 in SMAD2). Additionally, RBX1, CUL1, and GLMN formed a cluster, but none of these were on the list of cancer-related proteins. This cluster contained variants at Arg506, Gly543, and Glu758 in CUL1 and at Met50 in RBX1, which each occurred twice, and six remaining variants that were singletons (Supplementary Table 16 ).
Validation by protein array and functional experiment
In cancer, variants in the extracellular and kinase domains of receptor tyrosine kinases (RTKs) can cause ligand-independent kinase activation, leading to autophosphorylation. We focused on this phenomenon to validate the performance of HotSpot3D in identifying functional variants. Specifically, we first conducted validation using reverse-phase protein array (RPPA) expression data to assess whether the presence of predicted clusters in EGFR corresponded to higher levels of protein expression and/or autophosphorylation than observed with either the wild-type protein or EGFR with variants outside clusters. EGFR is an excellent test case because of the high number of variants found in this protein across multiple patient samples and because the two most significant clusters are highly TP53  PTEN  VHL  EGFR  FBXW7  PPP2R1A  PIK3R1  EP300  SMAD4  PIK3CA  CDKN2A  RAC1  CHEK2  BRAF  KRAS  ERBB2  RHOA  MAPK1  MAP2K1  KIT  HRAS  ERBB3  KEAP1  IDH1  FLT3  C6  SIRPA  MTOR  MARK3  HTRA3  ETV6  DNMT3A  IDH2   Hotspots   10   20 30 Clusters are labeled on the x axis, and bubble colors correspond to the member proteins. Empty bubbles indicate that a protein has new unique variants but does not have a hotspot variant. a n a ly s i s cancer type specific. The latter is important because RPPA results vary by cancer type. We used RPPA values to examine EGFR protein levels and assessed site-specific phosphorylation at the major autophosphorylation sites Tyr1173 and Tyr1068. We validated the two clusters in EGFR that exceeded the cluster closeness threshold, one specific to GBM with its centroid at Ala289 in the extracellular domain and the other specific to LUAD with its centroid at Leu858 in the kinase domain. Mean protein and phosphoprotein (Tyr1173 and Tyr1068) levels were significantly higher in GBM samples with mutations mapping to the Ala289 cluster than in samples with wild-type EGFR, at P = 2.3 × 10 −8 , P = 1.9 × 10 −5 , and P = 1.5 × 10 −6 , respectively (Fig. 6a) . Mean values for these measures were also higher than those in samples with EGFR variants outside of any cluster, but there were insufficient data to establish this observation as statistically significant. Almost all of the mutations mapping to the kinase domain in LUAD were from the Leu858 cluster, so we focus here on comparing EGFR with these variants to the wild-type protein. Mean protein and phosphoprotein (Tyr1173 and Tyr1068) levels were again significantly higher for samples harboring a variant in the Leu858 cluster, at P = 0.01, P = 0.04, and P = 4.6 × 10 −5 , respectively (Fig. 6a) . We also conducted validation on one ERBB2 cluster in the kinase domain having its centroid at p.Val842Ile using RPPA data for ERBB2 protein expression and autophosphorylation at Tyr1248. The trend was the same for this cluster as for the two EGFR clusters: the mean protein and phosphoprotein (Tyr1248) levels were highest for samples having mutations mapping to the p.Val842Ile cluster (Online Methods).
We also performed EGFR phosphorylation experiments for mutations mapping to the EGFR p.Leu858Arg cluster in cultured NIH3T3 cells to more conclusively assess functional predictions from HotSpot3D. This cluster included well-known substitutions such as p.Leu858Arg, p.Gly719Ala, and p.Thr790Met. Additional rare alterations having no available direct evidence of consequences for autophosphorylation included p.Asp761Asn, p.Ile789Met, p.Arg831His, and p.Leu833Phe, although a few reports have suggested weak or partial response to tyrosine kinase inhibitors in samples with other known druggable variants [23] [24] [25] . Our phosphorylation experiment targeting the Tyr1068 autophosphorylation site showed a low level of EGFR phosphorylation at Tyr1068 (0.21, normalized to the total EGFR amount) for the wild-type protein without epidermal growth factor (EGF) treatment (Fig. 6b) . EGFR protein with p.Leu858Arg, p.Gly719Ala, or p.Thr790Met had higher levels of normalized EGFR phosphorylation at Tyr1068 (0.79, 0.89, and 1.08, respectively), indicating ligand-independent kinase activation. The p.Asp761Asn, p.Ile789Met, p.Arg831His, and p.Leu833Phe variants also yielded higher levels of normalized EGFR phosphorylation at Tyr1068 (0.78, 0.38, 0.32, and 0.55, respectively), suggesting potential ligand-independent activation for these variants as well (Fig. 6b) . In addition, similar to p.Thr790Met and p.Gly719Ala, the p.Asp761Asn variant resulted in a much higher normalized level of EGFR npg a n a ly s i s phosphorylation at Tyr1068 (1.76) than was observed for the wild-type protein (1.08) under EGF stimulation. These observations demonstrate that some of the EGFR proteins with these variants do not just have ligand-independent activation; their levels of autophosphorylation upon EGF stimulation can be higher than those of wildtype EGFR (Fig. 6b and Supplementary Table 17) . Furthermore, we performed an experiment examining the sensitivity of the EGFR proteins with these variants to gefitinib. We found that EGFR with the p.Thr790Met variant was resistant to gefitinib, consistent with previous reports 26 . EGFR proteins with the other six variants were all sensitive to gefitinib (Fig. 6c) . In aggregate, these results furnish convincing evidence of the HotSpot3D clustering approach.
Mutation-drug networks and clinical implications
The HotSpot3D drug module targets variants in spatial proximity to actionable sites for pharmaceuticals and nutraceuticals derived from DrugPort (Online Methods Tables 18) .
Of particular interest, we have detected 48 protein kinases interacting with 21 drugs (Fig. 7b) , with strong variant-drug clusters found in EGFR, BRAF, KSR2, ERBB3, CDK7, CDK8, and ABL1. Our analysis also showed that 24 of the 394 variant-drug clusters had cluster closeness scores greater than 2.5 (Table 1) , including clusters in several protein kinases (BRAF, ERBB3, EGFR, PDK3, and NTRK1), nuclear hormone receptors (ESR1 and PPARD), and CD molecules (ACE, CD40LG, and ITGAX), as well as tumor suppressors (TP53 and VHL). Among the kinase-drug clusters, the cluster of BRAF (a serine/threonine kinase) with sorafenib (a tyrosine kinase inhibitor) topped the list because of hotspots at Val600 and Lys601 in BRAF. Interestingly, there were eight unique BRAF variants Lys601Glu) are present in at least one of these databases but have unknown effects on drug binding affinity. Our analysis lends weight to the potential druggability of the three unique BRAF variants with unknown functional consequences (Fig. 7c) . We also found two variant-drug clusters for ERBB3, for which eight of the nine unique variants were not catalogued in the databases (extracellular domain cluster: p.Val104Leu, p.Val104Met, n = 27 n = 17 n = 108 n = 27 n = 17 n = 108 n = 27 n = 17 n = 108 n = 19 n = 2 n = 117 n = 19 n = 2 n = 117 n = 19 n = 2 n = 117 a Figure 6 Functional assessment using phosphorylation data and experimental validation. npg a n a ly s i s (Fig. 7d) . None of the three variants (p.Arg299Cys, p.Arg299Ser, and p.Phe324Leu) from the PDK3 variant-drug cluster have been reported in the four databases of druggable mutations. The three variants in NTRK1 (p.Arg649Leu, p.Arg649Trp, and p.Arg702Cys) were likewise not found in these databases and are observed with an acetic ion binding in the C-terminal lobe adjacent to the binding pocket and DFG motif (within 10 Å). ESR1, PPARD, and PPARG topped the list of variant-drug clusters for the nuclear hormone receptor family (Supplementary Table 18) . The ESR1 cluster, with Cc = 4.6, had four unique variants interacting with five different compounds: raloxifene, estradiol, estrone, estriol, and diethylstilbestrol (Fig. 7e) . Raloxifene is a US Food and Drug Administration (FDA)-approved estrogen receptor modulator for reducing the risk of invasive breast cancer 27 , and estradiol, estrone, and estriol are estrogenic hormones functioning through ESR1. p.Arg394His and p.Arg394Leu variants in ESR1 formed significant pairs with all five compounds and could potentially affect responses (Fig. 7e) . HotSpot3D analysis suggests multiple putative therapeutic options for one mutation, but functional validation will still be required for confirmation and to determine which drug is most appropriate. Peroxisome-proliferator-activated receptor δ (PPARD) was found with two unique variants, p.His287Arg and p.His287Tyr, adjacent to icosapent, a micronutrient that has been used to treat a variety of symptoms and diseases and, most notably, has been suggested to improve chemotherapy response 28 . Another PPAR variantdrug cluster involved six unique PPARG variants associated with four drugs (indomethacin, pioglitazone, rosiglitazone, and telmisartan) (Supplementary Table 18 ). The action site for indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), neighbors all six variants of the cluster, and the action sites for pioglitazone and rosiglitazone (antidiabetic drugs) and telmisartan (an angiotensin II receptor antagonist (ARB)) neighbor two (p.Ile277Asn and p.Ile290Met), three (p.Ile290Met, p.Arg316Cys, and p.His494Tyr), and two (p.Arg316Cys and p.Glu352Lys) variants, respectively. It is noteworthy that, although none of these drugs has any previously known use in treating cancer, their action sites have all been found near a frequently mutated binding pocket in cancer. Both clusters in ESR1 and PPARG are present in the hormone receptor domain, suggesting that drug binding in this region might be affected by cancer-associated mutations.
The drug module in HotSpot3D allows users to identify mutationdrug clusters involving multiple drugs, as well as drugs interacting with mutations from multiple genes. For example, ABL1, from the eighth-ranked kinase cluster, interacts with four tyrosine kinase inhibitors: bosutinib, dasatinib, imatinib, and nilotinib; each of these has been used to treat patients with chronic myelogenous leukemia (CML) harboring BCR-ABL fusion 29, 30 . Although there were only three unique variants (p.Val390Leu, p.Asp400Tyr, and p.Phe401Leu) observed in the ABL1-drug cluster, the cluster closeness measure was appreciably increased owing to the four drugs involved. Asp400 and Phe401 residues, in the DFG motif, each control blocking of the binding pocket through conformational changes and therefore modulate the binding of imatinib and nilotinib. The gatekeeper in ABL1, Thr315, which controls ATP access to the binding pocket, was not found to be mutated in the TCGA data set studied, but the gatekeeper in EGFR, Thr790, was found in its own tyrosine kinase inhibitor variant-drug cluster with erlotinib, gefitinib, and lapatinib. Both Thr315 in ABL1 and Thr790 in EGFR have been shown to confer resistance to therapy with tyrosine kinase inhibitors, indicating that similarly positioned variants in gene families have the same effects within a drug class 31 . Further, we found that the DFG motif was also mutated in BTK (p.Phe540_Gly541delinsLeuCys), another tyrosine kinase. Notably, variants in three proteins, ABL1, BTK (including p.Leu528Phe), and BMX (p.Gly424Glu), were within the spatial interaction range of dasatinib (Supplementary Fig. 3) . Overall, HotSpot3D provides the means to identify complex, multidimensional interactions among drugs and variants and consequently to find alternative therapeutics that may provide greater flexibility in treating a wide range of genetic diseases.
DISCUSSION
The enormous numbers of available variants and protein structures offer an unprecedented resource for investigating the direct impact of variants on protein structure, which is fundamentally important to the design of targeted cancer drugs. Here we developed HotSpot3D to provide new capabilities not found in existing tools. First, HotSpot3D handles any mutation and variation data, has no limitation on the number of clusters per protein, and considers all available structures, thus maximizing the potential for discovery of new clusters and interactions in studies not limited to cancer. Second, it uses discovery of many different entities under a single algorithm-significant clusters within a single protein, at the interface of protein-protein complexes, and near drugs. To our knowledge, it is the first tool to effectively handle mutation-drug clusters. Third, it provides comprehensive downstream analyses in prioritizing clusters that are significantly enriched in mutations from multiple patient samples and supports the discovery of rare and medium-recurrent functional mutations.
We used HotSpot3D to analyze TCGA pan-cancer data, discovering a large set of mutations and identifying their relationships with known drivers. This is a rich resource for future functional explorations (Supplementary Table 22 ). Our HotSpot3D drug analysis also indicated that only 14 unique mutations in the significant mutation-drug clusters have been reported in the four standard databases we searched, implying discovery of over 800 new drug-interacting candidate mutations. The larger implications of this work are threefold: (i) the use of non-cancer drugs to treat cancers, (ii) the application of cancer-typespecific drugs to treat patients with other types of cancer, and (iii) the use of targeted drugs to treat patients with non-canonical cancerassociated variants that cluster with known druggable variants.
Although we have experimentally validated a small subset of predictions using high-throughput phosphorylation data and in vitro cellbased assays, additional experimental testing of all putative new drivers and drug-interacting mutations discovered in our study is required to confirm their biological functions. We envision that structurebased analyses using HotSpot3D will lead to discoveries of many types of relationships among variants undetectable by conventional approaches, for example, in human variations identified from populationbased studies, as well as germline variations and de novo mutations that have roles in many common diseases.
URLs. HotSpot3D code, https://github.com/ding-lab/hotspot3d; HUGO Gene Nomenclature Committee (HGNC), http://www. genenames.org/; Protein Data Bank (PDB), http://www.rcsb.org/; DrugPort, http://www.ebi.ac.uk/thornton-srv/databases/drugport/; npg a n a ly s i s ClinVar, http://www.clinvar.com/; HotSpot3D Visualization Portal code, https://github.com/ding-lab/hotspot3d_portal.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
HotSpot3D and code comparison. HotSpot3D (see URLs) has three parts: data preprocessing, structural analyses, and visualization (Fig. 1a) . For comparison with SpacePAC, we used the SimMax option, cluster radii of 2-10 Å, up to three clusters, and 1,000 simulated configurations. We restricted HotSpot3D to the single-molecule information available to SpacePAC and configured its parameters for an unbiased comparison: no linear separation, links formed with distance P values, and a maximum cluster radius of 10 Å. We retained only the most significant clusters for SpacePAC and used the average between-cluster distance for constituent residues as a test statistic. Permutation testing was performed for each cluster residue mass (number of residues in a cluster) for each structure. For cluster k of mass m, there are n = m(m -1)/2 residue pairs among all residues, which have an average of d k. For each m, we sampled 1 × 10 6 sets of n random pairs, and for the lth set we obtained the average between-cluster distance d l . The P value for the kth cluster of mass m is the proportion of sets with average inner distance less than d k .
Data preprocessing. Genes and their transcripts and proteins are procured from public sources, including the Human Genome Organization (HUGO). Preprocessing extracts four features from HGNC (see URLs): HGNC gene name, UniProt 32 ID, gene synonyms, and description.
UniProt is a comprehensive database for protein sequence and annotation data. For each HUGO gene, the UniProt ID was used to retrieve IDs from the PDB (see URLs), transcript and protein IDs from Ensembl, sequence from UniProt, and region of interest (ROI) information. For each ROI, corresponding information comprises the initial and destination coordinates of the UniProt sequence and specific function description. By comparing each UniProt sequence with all known and new peptide sequences from build GRCh37 of the human gnome (Ensembl release 74), we identified and kept only transcripts having the same translated length and sequence identity ≥98%. We only allowed one top Ensembl transcript match based on alignments with UniProt sequences.
This process culminates in an association table containing each HUGO gene, its UniProt, PDB, and transcript IDs, and sequence identity with UniProt sequence (Supplementary Table 23 ). This table was used for PDB-related three-dimensional distance calculations and conversion between PDB and UniProt coordinates. This information is stored in a MySQL database and a flat file.
Three-dimensional proximal-pairs analysis. Three-dimensional distance calculation. A UniProt ID enables protein structure data to be extracted from PDB 33 . For each of the 25,627 PDB structures, one or more chains could correspond to the UniProt sequence. Here we used the longest chain containing the amino acid of interest to calculate three-dimensional distances between amino acids. In cases of multiple identical models, one is picked randomly. We take intramolecular interactions to constitute any pair of amino acids from the same UniProt ID, regardless of chain in homomer complexes. Intermolecular pairs are between amino acids from different UniProt IDs within the same PDB structure.
Distance is calculated as follows. Given a pair of amino acids, AA 0 and AA 1 , and the respective sets of atomic coordinates for each in space, AA 0 and AA 1 where d is the distance between atoms i and j from AA 0 and AA 1 , respectively, and the amino acids range either over a single chain or over two chains, depending on context. Significance determination and prioritization. To calculate the significance of the distance between variants, we statistically analyzed all possible threedimensional distances within each PDB structure. A permutation-based P value for each pair of amino acids is the proportion of all pairwise threedimensional distances less than or equal to D(AA 0 , AA 1 ). To reduce the number of false positives due to proximal residues in primary sequence, amino acid pairs must be separated by at least ∆N residues along the protein sequence.
(1) (1) Here we use the following empirically derived criteria: P < 0.05, D ≤ 10 Å, and ∆N > 20 for intramolecular clusters and D ≤ 20 Å for intermolecular and variant-drug clusters. This procedure generates a data set consisting of the amino acid pairs and their three-dimensional distance, the linear distance, and the P value for each PDB structure.
Variant list input. For a given MAF or VCF input, transcript ID and amino acid change information from Ensembl annotation must be provided for each variant. Using the association table, variants map to specific UniProt IDs. From the three-dimensional proximity results, the amino acid change information is then used to map the variant to a specific location within the UniProt sequence. Using three-dimensional proximity results, Catalogue of Somatic Mutations in Cancer (COSMIC) annotation information, and ROI information, we conducted three-dimensional proximal-pairs analysis for a given variant list. Ultimately, our method reports five kinds of proximity information: variants in ROIs, variants close to ROIs, variants close to each other, variants at COSMIC locations, and variants close to COSMIC variants. Users can extract pairs of variants that are in close proximity to each other within a single protein, as well as in protein-protein complexes.
Drug interaction module. HotSpot3D includes a drug-protein interaction module based on data from DrugPort (see URLs), which contains structures of drugs and their target proteins in PDB, the latter derived from DrugBank 34 . The version of DrugPort used here contained 1,492 approved drugs and 1,664 unique protein targets, with 480 molecules in all (425 drugs and 55 nutraceuticals) contained within 21,603 PDB structures. Each drug has four attributes: number of different targets, number of targets with a known structure in PDB, number of drug-bound target structures, and total number of drug-bound structures. There is an important preprocessing step to establish the relationship between variants and the PDB structures containing each pharmaceutical. Using the DrugPort API, we parsed the raw DrugPort data file, obtaining DrugPort ID, PDB Het Group, drug molecule position in the PDB structure, and flag information. Het records describe non-standard residues, such as prosthetic groups, inhibitors, solvent molecules, and ions for which coordinates are supplied. Flag information identifies whether the structure is a target protein or is not a target protein but nevertheless contains the drug molecule. Using the preprocessing results as input for each drug, the HotSpot3D drugprotein interaction module can search variants to determine whether any are within the three-dimensional distance cutoff for each drug.
Cancer mutation data set and cancer types. We analyzed somatic mutations (Supplementary Table 24 ) from 4,405 TCGA tumor samples from 19 cancer types: bladder urothelial carcinoma (BLCA), breast adenocarcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon and rectal carcinoma (COAD and READ), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML; conventionally called AML), lower-grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous carcinoma (OV), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC).
Identifying mutation-mutation and mutation-drug clusters. Variants in proximal pairs are assigned to different clusters. To seed initial clusters, we start from significant proximal pairs, iteratively adding new variants if they are significantly paired with a variant already in that cluster. Because this procedure can form large clusters by the 'chaining effect' , as each addition lacks knowledge of the overall cluster size, we require a 'stopping rule' to limit growth. Specifically, we identify the centroid of the cluster as the variant having the highest closeness centrality and discard variants outside its threshold radius.
Formally, a cluster is an undirected graph G = (V, E), where V is a subset of the nonsynonymous variants from the input and E is the set of proximal pairs from V identified by HotSpot3D. Two options are available for selecting V: (i) the set of all non-truncating variants, V = V 1 , and (ii) the set of unique variants in the mutation cohort without recurrence, V = V 2 , (a proximity-only where N is the number of vertices in the cluster. For each cluster, the centroid is the vertex whose closeness centrality is the maximum. Finally, clusters can be focused according to user input for the cluster radius limit. The cluster radius limit is the maximum geodesic measured from the cluster centroid; any vertices outside this bound are pruned. For intramolecular clusters, we used pairs separated linearly by 20 peptides and a radius limit of 10 Å to keep clusters small and dense spatially. For intermolecular clusters, we used a larger limit of 20 Å, as we are spanning multiple proteins. Clustering for variant-drug pairs follows the same approach. Multiple instances of the same drug in a single protein are considered a single entity, despite the possibility of binding in several places. All variants significantly paired with the drug, regardless of binding location, are included in the initial cluster, even if the variants themselves are not close to one another. Conversely, one drug binding within a protein is treated separately from the same drug bound to other proteins, forming disjoint clusters; each cluster only includes variants from a single protein. The cluster radius is again 20 Å.
Prioritizing clusters with high cluster closeness values. We focused on top clusters for downstream analyses using cluster closeness (Cc) as a measure to establish thresholds. Cluster closeness is simply the sum of the closeness centralities over each variant in a cluster. High cluster closeness corresponds to spatially dense clusters enriched in variants from multiple patient samples. Here we distinguished between clusters with cancer-related proteins and those with non-cancer-related proteins. We generated cluster closeness distributions for both groups, using Wilcoxon testing to verify that they were significantly different and that cluster closeness was in fact a good metric to determine the functionality of clusters. We observed that clusters with cancer-related proteins had significantly higher cluster closeness than clusters without these proteins (P ≈ 5.3 × 10 −13 ). We could use the cluster closeness threshold to identify new cancer-related proteins that exhibit tightness and enrichment of variants in clusters similar to cancer-related proteins. We wanted a stringent cluster closeness threshold focusing on a small, conservative subset of intramolecular clusters, so we defined the threshold using the top 5% cutoff for the cancer-related protein group (Cc = 10.283; Fig. 2a) . To give an idea of the spatial tightness that this threshold implies, an idealized equilateral tetrahedron having all equal geodesic distances g would have a threshold of N 2 /2 g ≥ 10.283 from equation (2), whereby g ≤ ln(N 2 /10.283)/ln (2) . Substituting N = 4 for the tetrahedron, each vertex would be a distance of 0.64 Å at most from all the others. For intermolecular analysis, we distinguished clusters with all cancer-related proteins, at least one cancer-related protein, and no cancer-related proteins. We created cluster closeness distributions for all three groups. Here clusters with cancer-related proteins also had significantly higher cluster closeness values than clusters having none. Because there were fewer intermolecular clusters, we defined the threshold using the top 20% cutoff for the group with all cancer-related proteins (Cc = 4.118; Fig. 2b) , which is equivalent to a maximum geodesic distance of 1.96 Å in the idealized tetrahedron model.
Cluster conservation score. The phastCons score 36 quantifies conservation of mutated and deleted bases. Each cluster is scored by the weighted average of the phastCons scores for its variants, with variants weighted by recurrence. For each intramolecular cluster, we compared cluster closeness to the cluster conservation score to evaluate whether clusters occurred in functionally important regions:
70% (4,083 of 5,822 intramolecular clusters) had a high score (above 0.95). t testing of variants in clusters versus variants not in clusters showed the preference of clustered variants for conserved regions (P < 2.2 × 10 −16 ). Clusters with high cluster closeness tended to have a high conservation score, and we found 547 clusters from 542 cancer-related proteins, including all 38 of the top intramolecular clusters, among the group with high cluster conservation scores. Clusters of cancer-related proteins segregated as oncogenes, TSGs, or unclassified (general) cancer-related genes, and cluster conservation between groups was compared for clusters exhibiting high cluster closeness. t testing of clusters with top cluster closeness values failed to show significant differences between oncogenes and TSGs in terms of cluster conservation, both for the top 38 intramolecular clusters and the top 100 clusters (P = 0.1036 and 0.7733, respectively).
Cluster validation. Reverse-phase protein array data. Using the subset of the TCGA cohort having available RPPA data, we examined EGFR protein expression and site-specific phosphorylation at the major autophosphorylation sites Tyr1173 and Tyr1068. Here we discarded the linear limit on clustering because proximal variants in the linear sequence may be functionally relevant. We examined GBM samples, dividing them into three categories: those having variants from the EGFR Ala289 cluster, those having variants outside of any cluster, and those having no EGFR variant. The same method was applied to LUAD samples, with the p.Leu858Arg cluster being the cluster of interest. Protein and phosphoprotein levels were retrieved for the three categories. Welch's t test was used to determine whether the mean protein and phosphoprotein levels were significantly higher in samples from the first category as compared to samples from the other two categories. Similar methodology was used for ERBB2.
Phosphorylation functional experiments. NIH3T3 (clone 2.2) cells were kindly provided by R. Friesel. These cells have typical fibroblast morphology and undetectable levels of endogenous EGFR protein, which is characteristic of this subclone 37 ; they were negative for mycoplasma, as determined by the absence of extranuclear signals in DAPI staining. Cells were cultured in DMEM (Corning) supplemented with 10% calf serum (Thermo Fisher) and penicillin-streptomycin (Life Technologies). All plasmids for the expression of EGFR variants were generated from the plasmid with wild-type EGFR (Sino Biological) using Q5 site-directed mutagenesis (New England BioLabs). All constructs were confirmed by sequencing. Cells were transiently transfected with wild-type or mutant EGFR constructs using Lipofectamine 2000 reagent (Life Technologies) in six-well plates. Twenty-four hours after transfection, cells were switched to medium containing 0.5% calf serum for 24 h before stimulation with 50 ng/ml recombinant human EGF (R&D Systems) for 10 min. Cells were lysed in buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate , and 1 µg/ml leupeptin (Cell Signaling Technology). Protease and phosphatase inhibitors (Roche) were added immediately before use. Samples were boiled in buffer and subjected to SDS-PAGE on 10% polyacrylamide gels, and immunoblotting was performed on Immobilon-P PVDF membrane (Millipore). The following antibodies were used for immunoblotting: EGFR phosphorylated at Tyr1068 (Abcam, ab40815 at 1:500 dilution, Tyr1092 in unprocessed EGFR), EGFR (Abcam, ab2430 at 1:300 dilution) and β-tubulin (DSHB, E7 at 1:1,000 dilution). Appropriate secondary antibodies with infrared dyes (LI-COR) were used. Protein bands were visualized using the Odyssey Infrared Imaging System (LI-COR).
Mutation and drug annotations. ClinVar contains clinical variant annotation for 19,801 genes and 129,758 variants (see URLs). The Pancan19 MAF was annotated with available ClinVar clinical variant information. Of the 549,295 unique mutations observed in the TCGA data set, 805 had pathogenic information from ClinVar.
We curated mutations from four databases: MCG, PCT, GDKD, and CancerDR. MCG catalogs cancer-related mutations, therapeutic options, available clinical trials, and druggability information for 43 genes (including RTKs such as EGFR, KIT, and PDGFRA) and 289 relevant variants. PCT contains druggability information for variants of 24 cancer-related genes and over 140 variant-drug interactions supported by clinical evidence. GDKD provides information on predictive genomic markers for over 40 malignancies and tumor type sensitivity and resistance for specific gene variants to approved or experimental drugs. More than 700 variant-specific gene-drug interactions with therapeutic relevance were curated for this effort. CancerDR lists 148 anticancer drugs and their effectiveness against 1,000 cancer cell lines. Pharmacological profiles of these drugs were collected from the Cancer Cell Line Encyclopedia (CCLE) and COSMIC databases as IC 50 values. CancerDR contains information for 116 drug targets, including their corresponding gene sequences in cancer cell lines. Drug-sequence interactions that resulted in an IC 50 value ±2 s.d. from the mean were used.
Prioritized variant list for functional validation. We prioritized putative drivers that would be good candidates for experimental validation (Supplementary Table 22) by selecting rare and medium-recurrence variants appearing in clusters above the intramolecular and intermolecular cluster closeness thresholds. Variants were ranked according to closeness centralities, and only the top ten variants were included per gene.
Software engineering aspects.
We developed an interactive browser-based visualization portal (see URLs) to help assess whether a mutation interaction is likely to have functional importance. This maps individual variants onto a PDB structure, displays potentially interacting variant pairs or clusters, and provides for graphic annotation. Users can load individual mutations, multiple mutations, or HotSpot3D results and review all protein structures that contain the residues corresponding to the mutations. As an example, Supplementary Figure 4 shows two mutations from TCGA kidney cancer data, one in TCEB1 and the other in VHL. The client side of the portal runs within any native browser implementation, depending only on the Java plug-in to run the open source Jmol Java applet for displaying protein structures. The webserver is Apache Tomcat 7 running JSP programs and a Java servlet as an interface to access the underlying MySQL database of preprocessed biological information. The entire server runs on a Dell PowerEdge M620 blade server with one 8-core Intel Xeon E-2603 1.8-GHz CPU and 128 GB of RAM.
We analyzed clustering algorithm performance using robustness trials (Supplementary Note), where random mutations were chosen and run through the HotSpot3D clustering module. We observed O(N 3 ) time where N represents the number of input mutations, which is consistent with the characteristic time complexity of the Floyd-Warshall algorithm. Other algorithms that might provide performance gains would do so only under special constraints on the graph that are not guaranteed to exist for problems of this type.
